The Hindu Business Line : DRL gets USFDA nod for Citalopram

DR REDDY'S Laboratories Ltd has announced that the USFDA has granted final approval for the company's abbreviated new drug application (ANDA) for Citalopram hydrobromide tablets 10 mg, 20 mg and 40 mg.

In a press release, the company said it would commence the commercial marketing immediately.

Commenting on the development, the Dr Reddy's Chief Executive Officer, Mr G.V. Prasad, said: "We are pleased to be among the first to get the USFDA approval for Citalopram. We will be launching this product immediately through our own sales and marketing network and it represents a significant addition to our existing portfolio of generic products for the US market."

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
DRL gets USFDA nod for Citalopram

Ranbaxy approaches FDA for anti-AIDS drug

BEL pays 100 pc

Pawan Hans pays Rs 17.5-cr dividend

KK Birla Group to consolidate sugar business

Apollo Tyres completes due diligence of Modi Rubber tyre biz

50 pc of board must comprise non-executive directors: SEBI

Sona Koyo plans to hike investment in EOU — To set up dedicated power steering line for Hyundai

SRF plans Rs 285-crore expansion in four years

Tata Steel, L&T join hands for Dhamra port project

Tata group develops human development index

Zenith Finesse enters retail segment — In tie-up with Chinese co to sell audio-video equipment

`Indian firms must tap export potential of herbal drugs'

Hind Sanitaryware to issue 2:3 bonus